Impact Of Moxifloxacin On Exacerbation Frequency And Potential Pathogenic Microorganisms In Chronic Bronchitis
Main Article Content
Abstract
Chronic bronchitis is a typical respsiratory disorder that is typified by continuous cough, sputum, and inflammation of the airways, which may develop repetitive attacks in most cases. The period between these exacerbations which are usually caused by the bacterial pathogens may lead to frequent hospitalization and lung functioning deterioration. The aim of the study was to compare the effects of moxifloxacin, a fluoroquinolone antibiotic and placebo in exacerbation management and maintenance of potential pathogenic microorganisms (PPM) in the sputum of patients with chronic bronchitis. One hundred and sixty patients were randomly allocated to two groups, 80 patients received moxifloxacin and 80 patients received placebo. The main outcome was the rate of exacerbations and secondary ones were the results of the sputum culture, PCR to identify PPMs, and the presence of these microorganisms after 2 weeks, 8 weeks and 5 months of follow-up. The 2-week follow-up showed that the percent of patients with persistent PPMs in sputum was significantly lower with moxifloxacin than with placebo (25% vs. 70% p=0.01). Nevertheless, there was no major difference between the acquisition of new PPMs or long-term exacerbation. The logistic regression analysis demonstrated that when the follow-up was characterized by the acquisition of a new PPM, the risk of exacerbation was significantly high (OR 9.63, 95% CI: 1.0191.64). These results indicate that moxifloxacin might decrease the persistence of microbes in the short-term, but it is not clear how this drug will affect the preventive of new infections and exacerbation in the long term. Continuous monitoring of the new PPMs will be necessary in treating the chronic bronchitis attacks.
Article Details
References
Monso´ E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995;152: 1316–1320.
Zalacain R, Sobradillo V, Amilibia J, et al. Predisposing factors to bacterial colonisation in chronic obstructive pulmonary disease. Eur Respir J 1999; 13: 343–348.
Monso´ E, Rosell A, Bonet G, et al. Risk factors for lower airway bacterial colonisation in chronic bronchitis. Eur Respir J 1999; 13: 338–342.
Weinreich UM, Korsgaard J. Bacterial colonisation of lower airways in health and chronic lung disease. Clin Respir J 2008; 2: 116–122
Soler N, Ewig S, Torres A, et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 1015–1022.
Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000; 109: 288–295.
Sethi S, Maloney J, Grove L, et al. Airway inflammation and bronchial bacterial colonisation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 991–998.
Banerjee D, Khair OA, Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J 2004; 23: 685–691.
Patel IS, Seemungal TAR, Wilks M, et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759–764.
Wilkinson TMA, Patel IS, Wilks M, et al. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 1090–1095.
Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J 2002; 20: Suppl. 36, 9s–19s.
Niederman MS, Anzueto A, Sethi S,et al. Eradication of H. influenzae in AECB: a pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Respir Med 2006; 100: 1781–1790.
Miravitlles M. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Int J COPD 2007; 2: 191–204.
Wilson R, Allegra L, Huchon G, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953–964.
Miravitlles M, Molina J, Brosa M. Clinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and meta-analysis. Arch Bronconeumol 2007; 43: 16–21.